FDA granted Fast Track Designation to a Nuvation drug, while Jim Cramer shared stock opinions on CNBC.
2 reports, 1 independent
Updated Sep 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Fast Track Designation to a Nuvation drug, while Jim Cramer shared stock opinions on CNBC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Jim Cramer
American stockbroker, television personality, author
Related events
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- FDA granted Fast Track designation to NRX-100 on September 4, 2025.
- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
- Jim Cramer discussed packaged food stocks during a segment on CNBC on August 31, 2026.
- Jim Cramer reacted to CNBC's market reporting on X.